-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Bronchiectasis -X- _ O
unrelated -X- _ O
to -X- _ O
cystic -X- _ O
fibrosis -X- _ O
( -X- _ O
CF -X- _ O
) -X- _ O
is -X- _ O
being -X- _ O
increasingly -X- _ O
recognized -X- _ O
in -X- _ O
children -X- _ O
and -X- _ O
adults -X- _ O
globally -X- _ O
, -X- _ O
both -X- _ O
in -X- _ O
resource-poor -X- _ O
and -X- _ O
in -X- _ O
affluent -X- _ O
countries. -X- _ O
However -X- _ O
, -X- _ O
high- -X- _ O
quality -X- _ O
evidence -X- _ O
to -X- _ O
inform -X- _ O
management -X- _ O
is -X- _ O
scarce. -X- _ O
Oral -X- _ B-Intervention
amoxycillin-clavulanate -X- _ I-Intervention
is -X- _ O
often -X- _ O
the -X- _ O
first -X- _ O
antibiotic -X- _ O
chosen -X- _ O
for -X- _ O
non-severe -X- _ O
respiratory -X- _ O
exacerbations -X- _ O
, -X- _ O
because -X- _ O
of -X- _ O
the -X- _ O
antibiotic-susceptibility -X- _ O
patterns -X- _ O
detected -X- _ O
in -X- _ O
the -X- _ O
respiratory -X- _ O
pathogens -X- _ O
commonly -X- _ O
associated -X- _ O
with -X- _ O
bronchiectasis. -X- _ O
Azithromycin -X- _ B-Intervention
has -X- _ O
a -X- _ O
prolonged -X- _ O
half-life -X- _ O
, -X- _ O
and -X- _ O
with -X- _ O
its -X- _ O
unique -X- _ O
anti-bacterial -X- _ O
, -X- _ O
immunomodulatory -X- _ O
, -X- _ O
and -X- _ O
anti-inflammatory -X- _ O
properties -X- _ O
, -X- _ O
presents -X- _ O
an -X- _ O
attractive -X- _ O
alternative. -X- _ O
Our -X- _ O
proposed -X- _ O
study -X- _ O
will -X- _ O
test -X- _ O
the -X- _ O
hypothesis -X- _ O
that -X- _ O
oral -X- _ B-Intervention
azithromycin -X- _ I-Intervention
is -X- _ I-Intervention
non-inferior -X- _ I-Intervention
( -X- _ I-Intervention
within -X- _ I-Intervention
a -X- _ I-Intervention
20 -X- _ I-Intervention
% -X- _ I-Intervention
margin -X- _ I-Intervention
) -X- _ I-Intervention
to -X- _ I-Intervention
amoxycillin-clavulanate -X- _ I-Intervention
at -X- _ O
achieving -X- _ O
resolution -X- _ B-Outcome
of -X- _ I-Outcome
non-severe -X- _ I-Outcome
respiratory -X- _ I-Outcome
exacerbations -X- _ I-Outcome
by -X- _ I-Outcome
day -X- _ I-Outcome
21 -X- _ I-Outcome
of -X- _ O
treatment -X- _ O
in -X- _ O
children -X- _ B-Patient
with -X- _ I-Patient
non-CF -X- _ I-Patient
bronchiectasis. -X- _ I-Patient
METHODS -X- _ O
: -X- _ O
This -X- _ O
will -X- _ O
be -X- _ O
a -X- _ O
multicenter -X- _ O
, -X- _ O
randomized -X- _ O
, -X- _ O
double-blind -X- _ O
, -X- _ O
double-dummy -X- _ O
, -X- _ O
placebo-controlled -X- _ O
, -X- _ O
parallel -X- _ O
group -X- _ O
trial -X- _ O
involving -X- _ O
six -X- _ O
Australian -X- _ O
and -X- _ O
New -X- _ O
Zealand -X- _ O
centers. -X- _ O
In -X- _ O
total -X- _ O
, -X- _ O
170 -X- _ B-Patient
eligible -X- _ I-Patient
children -X- _ I-Patient
will -X- _ O
be -X- _ O
stratified -X- _ O
by -X- _ O
site -X- _ O
and -X- _ O
bronchiectasis -X- _ O
etiology -X- _ O
, -X- _ O
and -X- _ O
randomized -X- _ B-Intervention
( -X- _ I-Intervention
allocation -X- _ I-Intervention
concealed -X- _ I-Intervention
) -X- _ I-Intervention
to -X- _ I-Intervention
receive -X- _ I-Intervention
: -X- _ I-Intervention
1 -X- _ I-Intervention
) -X- _ I-Intervention
azithromycin -X- _ I-Intervention
( -X- _ I-Intervention
5 -X- _ I-Intervention
mg -X- _ I-Intervention
/ -X- _ I-Intervention
kg -X- _ I-Intervention
daily -X- _ I-Intervention
) -X- _ I-Intervention
with -X- _ I-Intervention
placebo -X- _ I-Intervention
amoxycillin-clavulanate -X- _ I-Intervention
or -X- _ I-Intervention
2 -X- _ I-Intervention
) -X- _ I-Intervention
amoxycillin-clavulanate -X- _ I-Intervention
( -X- _ I-Intervention
22.5 -X- _ I-Intervention
mg -X- _ I-Intervention
/ -X- _ I-Intervention
kg -X- _ I-Intervention
twice -X- _ I-Intervention
daily -X- _ I-Intervention
) -X- _ I-Intervention
with -X- _ I-Intervention
placebo -X- _ I-Intervention
azithromycin -X- _ I-Intervention
for -X- _ I-Intervention
21 -X- _ I-Intervention
days -X- _ I-Intervention
as -X- _ I-Intervention
treatment -X- _ I-Intervention
for -X- _ O
non-severe -X- _ B-Patient
respiratory -X- _ I-Patient
exacerbations. -X- _ I-Patient
Clinical -X- _ O
data -X- _ O
and -X- _ O
a -X- _ O
parent-proxy -X- _ O
cough-specific -X- _ O
quality -X- _ O
of -X- _ O
life -X- _ O
( -X- _ O
PC-QOL -X- _ O
) -X- _ O
score -X- _ O
will -X- _ O
be -X- _ O
obtained -X- _ O
at -X- _ O
baseline -X- _ O
, -X- _ O
at -X- _ O
the -X- _ O
start -X- _ O
and -X- _ O
resolution -X- _ O
of -X- _ O
exacerbations -X- _ O
, -X- _ O
and -X- _ O
on -X- _ O
day -X- _ O
21. -X- _ O
In -X- _ O
most -X- _ O
children -X- _ O
, -X- _ O
blood -X- _ O
and -X- _ O
deep-nasal -X- _ O
swabs -X- _ O
will -X- _ O
also -X- _ O
be -X- _ O
collected -X- _ O
at -X- _ O
the -X- _ O
same -X- _ O
time -X- _ O
points. -X- _ O
The -X- _ O
primary -X- _ O
outcome -X- _ O
is -X- _ O
the -X- _ O
proportion -X- _ O
of -X- _ O
children -X- _ O
whose -X- _ O
exacerbations -X- _ O
have -X- _ O
resolved -X- _ O
at -X- _ O
day -X- _ O
21. -X- _ O
The -X- _ O
main -X- _ O
secondary -X- _ O
outcome -X- _ O
is -X- _ O
the -X- _ O
PC- -X- _ O
QOL -X- _ O
score. -X- _ O
Other -X- _ O
outcomes -X- _ O
are -X- _ O
: -X- _ O
time -X- _ O
to -X- _ O
next -X- _ O
exacerbation -X- _ O
; -X- _ O
requirement -X- _ O
for -X- _ O
hospitalization -X- _ O
; -X- _ O
duration -X- _ O
of -X- _ O
exacerbation -X- _ O
, -X- _ O
and -X- _ O
spirometry -X- _ O
data. -X- _ O
Descriptive -X- _ O
viral -X- _ O
and -X- _ O
bacteriological -X- _ O
data -X- _ O
from -X- _ O
nasal -X- _ O
samples -X- _ O
and -X- _ O
blood -X- _ O
inflammatory -X- _ O
markers -X- _ O
will -X- _ O
be -X- _ O
reported -X- _ O
where -X- _ O
available. -X- _ O
DISCUSSION -X- _ O
: -X- _ O
Currently -X- _ O
, -X- _ O
there -X- _ O
are -X- _ O
no -X- _ O
published -X- _ O
randomized -X- _ O
controlled -X- _ O
trials -X- _ O
( -X- _ O
RCT -X- _ O
) -X- _ O
to -X- _ O
underpin -X- _ O
effective -X- _ O
, -X- _ O
evidence-based -X- _ O
management -X- _ O
of -X- _ O
acute -X- _ B-Patient
respiratory -X- _ I-Patient
exacerbations -X- _ I-Patient
in -X- _ I-Patient
children -X- _ I-Patient
with -X- _ I-Patient
non-CF -X- _ I-Patient
bronchiectasis. -X- _ I-Patient
To -X- _ O
help -X- _ O
address -X- _ O
this -X- _ O
information -X- _ O
gap -X- _ O
, -X- _ O
we -X- _ O
are -X- _ O
conducting -X- _ O
two -X- _ O
RCTs. -X- _ O
The -X- _ O
first -X- _ O
( -X- _ O
bronchiectasis -X- _ O
exacerbation -X- _ O
study -X- _ O
; -X- _ O
BEST-1 -X- _ O
) -X- _ O
evaluates -X- _ O
the -X- _ O
efficacy -X- _ O
of -X- _ O
azithromycin -X- _ B-Intervention
and -X- _ I-Intervention
amoxycillin-clavulanate -X- _ I-Intervention
compared -X- _ B-Comparison
with -X- _ I-Comparison
placebo -X- _ I-Comparison
, -X- _ O
and -X- _ O
the -X- _ O
second -X- _ O
RCT -X- _ O
( -X- _ O
BEST-2 -X- _ O
) -X- _ O
, -X- _ O
described -X- _ O
here -X- _ O
, -X- _ O
is -X- _ O
designed -X- _ O
to -X- _ O
determine -X- _ O
if -X- _ O
azithromycin -X- _ B-Intervention
is -X- _ I-Intervention
non-inferior -X- _ I-Intervention
to -X- _ I-Intervention
amoxycillin-clavulanate -X- _ I-Intervention
in -X- _ O
achieving -X- _ O
symptom -X- _ O
resolution -X- _ O
by -X- _ O
day -X- _ O
21 -X- _ O
of -X- _ O
treatment -X- _ O
in -X- _ O
children -X- _ B-Patient
with -X- _ I-Patient
acute -X- _ I-Patient
respiratory -X- _ I-Patient
exacerbations. -X- _ I-Patient
TRIAL -X- _ O
REGISTRATION -X- _ O
: -X- _ O
Australia -X- _ O
and -X- _ O
New -X- _ O
Zealand -X- _ O
Clinical -X- _ O
Trials -X- _ O
Register -X- _ O
( -X- _ O
ANZCTR -X- _ O
) -X- _ O
number -X- _ O
http -X- _ O
: -X- _ O
/ -X- _ O
/ -X- _ O
ACTRN12612000010897. -X- _ O
http -X- _ O
: -X- _ O
/ -X- _ O
/ -X- _ O
www.anzctr.org.au -X- _ O
/ -X- _ O
trial_view.aspx -X- _ O
? -X- _ O
id=347879 -X- _ O

